Special Issue "Targeting Proteins—in-Silico, In-Vitro, and In-Vivo Evidence"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1509

Special Issue Editors

1. Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
2. Center for Physiology and Pharmacology, Institute of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria
Interests: protein analysis; drug discovery; in silico evaluation; in vitro and in vivo analysis
Special Issues, Collections and Topics in MDPI journals
1. Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria
2. ScienceConsult - DI Thomas Mohr KG, Enzianweg 10a, 2353 Guntramsdorf, Austria
Interests: bioinformatics; systems biology; cancer; biomarker identification; network analysis; omics analysis; in-vitro test development; data integration
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeting cellular proteins is critical in order to change the behavior of cells. Recent scientific advances, especially in the field of high-throughput proteomics and molecular simulations, have enabled us to delve deeper into the field of protein interactions; this is of significant importance for gaining novel insights into biological processes and finding previously unknown potential drug targets.

In this Special Issue of Biomedicines, we are interested in original research on the targeting of proteins, especially regarding their druggability, whether this be in silico, in vitro or in vivo. This Special Issue will focus on manuscripts that link the wet lab and the dry lab. However, papers will be considered case-by-case, based on their overall merit.

Dr. Alexander Tolios
Dr. Thomas Mohr
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • protein analysis
  • drug discovery
  • in silico evaluation
  • in vitro and in vivo analysis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation
Biomedicines 2022, 10(9), 2270; https://doi.org/10.3390/biomedicines10092270 - 13 Sep 2022
Cited by 1 | Viewed by 1058
Background: Mechanisms by which chronic kidney disease (CKD) influences fibrin clot properties in atrial fibrillation (AF) remain ill-defined. We aimed to investigate the effects of AF and CKD on fibrin clot properties and lipoproteins, and determine the relationship between these factors. Methods [...] Read more.
Background: Mechanisms by which chronic kidney disease (CKD) influences fibrin clot properties in atrial fibrillation (AF) remain ill-defined. We aimed to investigate the effects of AF and CKD on fibrin clot properties and lipoproteins, and determine the relationship between these factors. Methods: Prospective cross-sectional study of patients recruited from cardiology services in Liverpool between September 2019 and October 2021. Primary groups consisted of anticoagulated AF patients with and without CKD in a 1:1 ratio. Control group comprised anticoagulated patients without AF or CKD. Fibrin clot properties were analysed using turbidity and permeation assays. Detailed lipoprotein characteristics, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), small dense LDL and oxidised LDL, were measured. Results: Fifty-six anticoagulated patients were enrolled (median age 72.5; 34% female); 46 with AF (23 with CKD and 23 without CKD) and 10 controls. AF was associated with changes in three indices of fibrin clot properties using PTT (Tlag 314 vs. 358 s, p = 0.047; Abspeak 0.153 vs. 0.111 units, p = 0.031; Tlysis50% 884 vs. 280 s, p = 0.047) and thrombin reagents (Tlag 170 vs. 132 s, p = 0.031; Tmax 590 vs. 462 s, p = 0.047; Tpeak50% 406 vs. 220 s, p = 0.005) while the concomitant presence of CKD led to changes in fibrin clot properties using kaolin (Tlag 1072 vs. 1640 s, p = 0.003; Tmax 1458 vs. 1962 s, p = 0.005; Tpeak50% 1294 vs. 2046, p = 0.008) and PPP reagents (Tlag 566 vs. 748 s, p = 0.044). Neither of these conditions were associated with changes in fibrin clot permeability. Deteriorating eGFR was significantly correlated to the speed of clot formation, and CKD was independently associated with unfavourable clot properties (Tlag −778, p = 0.002; Tmax −867, p = 0.004; Tpeak50% −853, p = 0.004 with kaolin reagent). AF alone was not associated with changes in lipoprotein distribution while AF patients with CKD had lower total cholesterol, LDL-C and small dense LDL due to the presence of other risk factors. No significant relationship was observed between fibrin clot properties and lipoprotein distribution. Conclusions: There are important changes that occur in fibrin clot properties with AF and CKD that may account for the increased risk of thromboembolic complications. However, these changes in fibrin clot properties were not attributable to alterations in lipoprotein distribution. Full article
(This article belongs to the Special Issue Targeting Proteins—in-Silico, In-Vitro, and In-Vivo Evidence)
Back to TopTop